Aldo P. Maggioni

Research interests

Publications

• European Society of Cardiology: cardiovascular disease statistics 2021

  European Heart Journal · 2021 · https://doi.org/10.1093/eurheartj/ehab892

• Initial Invasive or Conservative Strategy for Stable Coronary Disease

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1915922

• Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1912388

• European Society of Cardiology: Cardiovascular Disease Statistics 2019

  European Heart Journal · 2019 · https://doi.org/10.1093/eurheartj/ehz859

• Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

  The Lancet · 2019 · 10.1016/s0140-6736(18)31942-1

• Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry

  European Journal of Preventive Cardiology · 2019 · 10.1177/2047487318825350

• Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study

  European Heart Journal · 2019 · https://doi.org/10.1093/eurheartj/ehz620

• Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

  New England Journal of Medicine · 2019 · 10.1056/nejmoa1908655

• Type 2 Diabetes Mellitus and Heart Failure: A Position Statement from the Heart Failure Association of the European Society of Cardiology

  European Journal of Heart Failure · 2018 · 10.1002/ejhf.1170

• Clinical Phenotypes and Outcome of Patients Hospitalized for Acute Heart Failure: The ESC Heart Failure Long-Term Registry

  European Journal of Heart Failure · 2017 · 10.1002/ejhf.890

• Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

  New England Journal of Medicine · 2017 · 10.1056/nejmoa1709118

• Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

  The Lancet · 2017 · 10.1016/s0140-6736(17)32409-1

• Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

  The Lancet · 2017 · 10.1016/s0140-6736(17)32458-3

• Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

  New England Journal of Medicine · 2017 · 10.1056/nejmoa1612917

• Epidemiology and One-Year Outcomes in Patients With Chronic Heart Failure and Preserved, Mid-Range and Reduced Ejection Fraction: An Analysis of The ESC Heart Failure Long-Term Registry

  European Journal of Heart Failure · 2017 · 10.1002/ejhf.813

• European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-Year Follow-Up Outcomes and Differences Across Regions

  European Journal of Heart Failure · 2016 · 10.1002/ejhf.566

• Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1509225

• HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

  The Lancet · 2014 · 10.1016/s0140-6736(14)61183-1

• EUR Observational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)

  European Journal of Heart Failure · 2013 · 10.1093/eurjhf/hft050

• Are Hospitalized or Ambulatory Patients with Heart Failure Treated in Accordance with European Society of Cardiology Guidelines? Evidence from 12 440 Patients of the ESC Heart Failure Long-Term Registry

  European Journal of Heart Failure · 2013 · 10.1093/eurjhf/hft134

• ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

  European Heart Journal · 2012 · https://doi.org/10.1093/eurheartj/ehs104

• Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies

  European Heart Journal · 2012 · 10.1093/eurheartj/ehs337

• ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012

  European Journal of Heart Failure · 2012 · https://doi.org/10.1093/eurjhf/hfs105

• Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

  The Lancet · 2010 · https://doi.org/10.1016/s0140-6736(09)61965-6

• Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects

  New England Journal of Medicine · 2010 · 10.1056/nejmoa1003114

• Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial

  The Lancet · 2008 · 10.1016/s0140-6736(08)61236-2

• The Seattle Heart Failure Model

  Circulation · 2006 · 10.1161/circulationaha.105.584102

• Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction

  New England Journal of Medicine · 2004 · 10.1056/nejmoa041365

• Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both

  New England Journal of Medicine · 2003 · https://doi.org/10.1056/nejmoa032292

• Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction

  Circulation · 2002 · 10.1161/01.cir.0000014682.14181.f2

• ISIS-4 - A randomised factorial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58.050 patient with suspected acute myocardial-infarction.

  Ghent University Academic Bibliography (Ghent University) · 1995

• ISIS-3 - A RANDOMIZED COMPARISON OF STREPTOKINASE VS TISSUE PLASMINOGEN-ACTIVATOR VS ANISTREPLASE AND OF ASPIRIN PLUS HEPARIN VS ASPIRIN ALONE AMONG 41,299 CASES OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION

  The Lancet · 1992

Current projects

No projects listed.